AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
i Clinical Study Protocol M11-352. AbbVie. Date Accessed: April 1, 2013.
ii European Renal Association - European Dialysis and Transplantation Association (ERA-EDTA). Oral Presentation 034932, "The Selective Type A Endothelin Antagonist Atrasentan Reduces Residual Albuminuria in Patients with Type 2 Diabetes and Nephropathy."iii Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States. The Journal of the American Medical Association. Date Accessed: October 28, 2011. iv Diabetic Nephropathy. Cleveland Clinic. Available at: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/nephrology/diabetic-nephropathy/. Date Accessed: April 22, 2013. v IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Atlas. Date Accessed: May 2, 2013. vi Medical Care Costs Associated With Progression of Diabetic Nephropathy. Diabetes Care. Date Accessed: May 2, 2013. vii Kidney Disease of Diabetes. National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC). Accessed: May 2, 2013 SOURCE AbbVie